Literature DB >> 7726250

An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy.

K D Hatch1, A Schneider, M W Abdel-Nour.   

Abstract

OBJECTIVE: Our purpose was to evaluate the role of testing for intermediate- and high-risk human papillomavirus by use of a hybrid capture technique for predicting which patients with abnormal Papanicolaou smears are most likely to have squamous intraepithelial lesions or cancer. STUDY
DESIGN: Cervical cytologic studies, hybrid capture tests, and colposcopically directed biopsies were performed on 311 women referred to the colposcopy clinics with abnormal cytologic study results.
RESULTS: There was a highly significant correlation (p < 0.0001) between a positive human papillomavirus test and the finding of squamous intraepithelial lesions or invasive cancer. The sensitivity of human papillomavirus testing to detect high-grade squamous intraepithelial lesions was 74% when it was used alone and increased to 91% when coupled with abnormal cytologic study results of low- or high-grade squamous intraepithelial lesions or cancer. In 44 women with atypical squamous cells of undetermined significance on cytologic study, human papillomavirus testing identified six of 10 who had high-grade squamous intraepithelial lesions. For the 96 patients with low-grade squamous intraepithelial lesions, human papillomavirus testing was successful in identifying 29 of the 37 with high-grade squamous intraepithelial lesions (sensitivity 0.76).
CONCLUSION: Testing for intermediate- and high-risk human papillomavirus types by hybrid capture improves the detection of high-grade squamous intraepithelial lesions in women with atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions over cytologic study used alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726250     DOI: 10.1016/0002-9378(95)91473-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay.

Authors:  I Nindl; B Lotz; R Kühne-Heid; U Endisch; A Schneider
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

2.  Human papillomaviruses and cervical screening.

Authors:  I J Etherington; M I Shafi
Journal:  Genitourin Med       Date:  1996-06

3.  Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection.

Authors:  K V Shah; L Solomon; R Daniel; S Cohn; D Vlahov
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

4.  Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison.

Authors:  M V Jacobs; P J Snijders; F J Voorhorst; J Dillner; O Forslund; B Johansson; M von Knebel Doeberitz; C J Meijer; T Meyer; I Nindl; H Pfister; E Stockfleth; A Strand; G Wadell; J M Walboomers
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

5.  Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions.

Authors:  C Clavel; M Masure; I Putaud; K Thomas; J P Bory; R Gabriel; C Quereux; P Birembaut
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

6.  HPV testing in primary screening of older women.

Authors:  J Cuzick; E Beverley; L Ho; G Terry; H Sapper; I Mielzynska; A Lorincz; W K Chan; T Krausz; P Soutter
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

7.  Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women.

Authors:  C Clavel; M Masure; J P Bory; I Putaud; C Mangeonjean; M Lorenzato; R Gabriel; C Quereux; P Birembaut
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.